Document is current
Any future updates will be listed below
-
Authors
Nageshan, Rishi Kumar
Ortega, Raquel
Krogan, Nevan https://orcid.org/0000-0003-4902-337X
Cooper, Julia Promisel https://orcid.org/0000-0003-2171-2587
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (GM145820-01)
University of Colorado Anschutz Medical Campus National Cancer Institute intramural funds
- License Information
-
More Information
Article History
Received: 21 January 2024
Accepted: 29 April 2024
First Online: 3 June 2024
Competing interests
: The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. N.K. has a financially compensated consulting agreement with Maze Therapeutics. N.K. is the President and is on the Board of Directors of Rezo Therapeutics, and he is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and Interline Therapeutics. The remaining authors declare no competing interests.
